(UPN 23) and three patients did not show additional alterations (UPNs 24-26). However, one patient of the latter group had already presented an additional NRAS codon 12 mutation at initial MDS diagnosis. One patient developed a second RUNX1 mutation along with trisomy 13 (UPN 22). Interestingly, both patients who gained a chromosome 13 (UPNs 1 and 22) had antecedent mutations in RUNX1. According to current literature, RUNX1 mutations occur at a frequency of about 15% in MDS, 7 thus the rate of RUNX1 mutations is increased in our patient cohort, which is defined by leukemic evolution. Thus, our results suggest that the detection of RUNX1 mutations in MDS comes along with a propensity to leukemic transformation. FLT3-ITDs occurred only after progression to s-AML in our cohort. Both patients who gained FLT3-ITDs in the progression from MDS to s-AML presented antecedent mutations in RUNX1. These two patients fit nicely into the two-hit hypothesis for the pathogenesis of AML with RUNX1 mutations altering gene expression (type I mutation) and FLT3-ITDs leading to enhanced proliferation (type II mutation). 8 In the present study, RUNX1, a known cancer gene, is located in a region affected by UPD. In this patient, a heterozygous RUNX1 mutation has been found at MDS diagnosis. LOH of the remaining healthy RUNX1 allele due to UPD was accompanied by progression to s-AML within less than 6 months after initial MDS diagnosis. The contribution of UPD to s-AML evolution sheds light on a novel aspect regarding the progression from MDS to s-AML. The second genetic hit is neither an additional mutation nor a cytogenetic alteration but rather the duplication of a RUNX1-mutated allele leading to LOH of the unaffected allele.
From a genetic point of view, MDS and AML show an overlapping pattern of cytogenetic and molecular genetic abnormalities. With the exception of AML-specific recurrent balanced rearrangement, mostly unbalanced abnormalities occur both in MDS and AML.
In conclusion, our data demonstrate that 60% (23/38) of patients acquired additional genetic abnormalities during progression from MDS to s-AML. One group (24%) preferentially gained additional chromosome abnormalities while the other group (26%) was characterized by additional molecular mutations. Four patients (11%) presented both additional cytogenetic and molecular genetic changes, one of which acquired UPD(21q) with RUNX1-LOH in the course of s-AML development. While RUNX1 mutations already occurred at a high frequency at MDS stage, mutations in FLT3 were seen only after progression to s-AML.
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International Scoring System for evaluating prognosis in myelodysplastic syndromes. þ , B-cell receptor (BCR) low immunophenotype in peripheral blood (PB) and bone marrow, frequently in association with involvement of other lymphoid tissues, disease symptoms and a heterogeneous clinical outcome. In parallel, monoclonal B-cell lymphocytosis (MBL), typically characterized by an expansion of clonal CLL-like B-cells (o5 Â 10 9 cells per l), has been also frequently reported in otherwise asymptomatic subjects.
1,2 Increasing evidence suggests that this could represent a pre-leukemic condition, as CLL frequently develops in individuals with previous history of MBL, and MBL cases progress to CLL at a rate of 1% per year.
2,3
Letters to the Editor Interestingly, in addition to MBL cases presenting with lymphocytosis, very low numbers of clonal B-cells with a CLL-like immunophenotype and cytogenetic profile, are also present in healthy subjects with normal lymphocyte counts. 2 Initially, a frequency of CLL-like clones among healthy adults of around 3-6% was reported. Despite this relatively high incidence, controversial results have been reported about the precise frequency of CLL-like MBL in the general population.
2,4,5 Such variability has been related to genetic and microenvironmental differences, as well as to technical variables associated with different sensitivities of the distinct methods applied.
4,5 Accordingly, we have recently shown that the actual frequency of MBL cases presenting with normal lymphocyte counts could increase to as high as 12% of the general adult population 440 years, 4 depending on the sensitivity of the method and the volume of blood screened, in addition to age. Altogether, these observations raise the question about the actual frequency and significance of such small B-cell clones in normal subjects, as regards their pathological vs physiological nature.
Here, we provide further evidence about the great prevalence of small numbers of CLL-like B-cells among adults of increasing age, supporting the notion that they might be present among virtually every subject older than 70 years. Our results are based on the analysis of the frequency of CLL-like MBL in 639 healthy adults (440 years old) with normal lymphocyte counts, representative of the population living in the area of Salamanca (Western Spain), in whom we investigated the association between the frequency of CLL-like MBL and the volume of sample analyzed. These subjects included a series of 608 previously reported individuals plus 31 new subjects recruited according to the same criteria and who were investigated for the presence of CLL-like MBL in between 0.9 and 1.2 ml of PB, using previously described flow cytometry approaches; 4 in a subgroup of nine donors aged 470 years, who did not show evidence of CLL-like B-cells in the screening phase, a second 50 ml PB sample was obtained and further investigated for the presence of CLL-like B-cell clones (see Supplementary text for more detailed information).
Overall, 80/639 subjects studied (12.5%) showed CLL-like clones defined by the presence of 450 cellular events with a CLL-like aberrant phenotype (CD19
±dim Cybcl2 hi and restricted expression of immunoglobulin ligh-chain þ dim in the absence of CD10) in the overall sample analyzed (median PB volume: 1200 ml; range: 900-1200 ml). Letters to the Editor 0.010-0.101) and leucocytes (median of 0.008; interquartile range: 0.002-0.028) was similar to that reported for the first 608 cases. 4 As for the initial 608 cases, 4 a progressively higher frequency of individuals carrying CLL-like B-cell clones was detected in parallel to increasing age: 5.4% of subjects aged 40-49 years, 15.5% in the 60-69 age range and 19.2% in those older than 70 years.
Based on the sequence of acquisition of data in the flow cytometer for single PB leucocytes, then we determined for each MBL case the specific number of cells that were measured (and the corresponding volume of PB) to reach the preestablished threshold of 50 CLL-like B-cells to consider that case as MBL. As shown in Figure 1 (Column A), a progressive increase in the frequency of cases with CLL-like B-cell clones was detected, according to the volume of sample interrogated (from 1 to 1200 ml) from 0 to 15.8-95% confidence interval (CI): 13.8-17.9%F, respectively. Upon grouping the subjects according to age, similar profiles were observed, but with significantly higher frequencies for adults aged X60 years, and particularly those aged X70 years vs subjects aged 40-59 years: 18.6% (95% CI: 15.8-21.4%) for cases X60 and o70 years, and 24.8% (95% CI: 21.2-28.4%) for those aged X70 years vs 6.7% (95% CI: 5.9-7.4%) for subjects o60 years ( Figure 1 , Column A).
According to the overall pattern of increase in the frequency of positive cases observed when progressively higher volumes of sample were measured, a mathematical model was then built to predict whether PB CLL-like B-cells could be detected in virtually every case, if larger volumes of PB had been screened for each subject (Figure 1, Column B) . Based on the 95% lower CI bound, this model predicted that CLL-like B-cells could be detected in every subject 470 years if around 50 ml of their PB would had been analyzed (the lower limit of the 95% CI reached 100% for PB volumes of around 46 ml). According to this model, in the hypothetical case that the same volume of PB (46 ml) would be stained and analyzed for each subject in the other age groups, the estimated frequency of cases carrying CLL-like clones for subjects studied at 40-59 years of age was of 32% (95% CI: 18-46%) and of 62% for cases with 60-69 years (95% CI: 36-88%), with an estimated rate of 100% for the whole series (lower limit of the 95% CI of 70%) (Figure 1 , Column B).
Based on this prediction, AutoMACS-enriched B-cell preparations were obtained from another B50 ml of PB from nine subjects aged 470 years (median of 77 years, from 72 to 88 years) who did not show detectable CLL-like B-cells when between 0.9 and 1.2 ml of their PB had been analyzed, and were further investigated (Supplementary Material). Our results confirmed the presence of CLL-like B-cells in all but one of them (Table 1 and Supplementary Figure 1) . Noteworthy, both sIgk þ and sIgl þ CLL-like B-cell populations were detected in 4/9 of these MBL cases, even with a normally balanced sIgk/sIgl ratio in one of them (Case no. 8 in Table 1 ). Based on these results it could be speculated that the systematic presence of CLL-like B-cells at very low numbers in adults with advanced age (for example, 470 years), more likely represents the normal counterpart of CLL malignant cells than a leukemic B-cell precursor.
In the last decades, an increased degree of genetic predisposition with familial cases has been reported for some CLL patients. However, this does not explain the occurrence of most (sporadic) CLL and/or MBL cases. In this regard, recent epidemiological data, 6 together with studies showing that CLL and MBL B-cells frequently display stereotyped B-cell receptors, 3 suggest that antigen-driven immunological responses Table 1 Characteristics of CLL-like B-cells identified in 50 ml of PB from nine healthy subjects older than 70 years, who did not show MBL when 0.9-1.2 ml of PB had been screened could contribute to trigger the expansion (and potentially also the malignant transformation) of small CLL-like B-cell clones. In contrast to CLL, information currently available about the immunoglobulin heavy chain variable repertoire of CLL-like MBL B-cell clones in the general population is limited and does not allow any definitive conclusion. 7 However, preliminary data about the immunoglobulin heavy chain variable repertoire of CLL-like clones from subjects with MBL and normal B-cell counts, point out a relatively low frequency of usage of those immunoglobulin heavy chain variable segments, which are more frequently observed in CLL and MBL associated with absolute B-cell lymphocytosis. 7 The potential association in these latter cases of CLL-like clones with a physiological process related to chronic immune stimulation would be further supported by the reported increase in the frequency of CLLlike clones with age. 4 Previous studies have shown that marked age-related changes occur in the PB B-cell compartment, particularly among individuals 460 years, with a significant decrease in both memory B-cells and circulating plasma cells. Such changes cannot be attributable to a decreased B-cell production, but more likely they reflect either a decreased recruitment of naïve B lymphocytes or a low ability of the memory B-cell compartment to expand. In such a case, immunosurveillance against chronic immune stimuli could only be effective if long-living cells are formed, that is, antigenspecific B-cells could enter into a long-living 'senescent-like' status. Therefore, a crucial question remains about whether these changes are actually found under physiological conditions in every subject, at least once a certain age is reached. Based on the increasing frequencies of CLL-like clones detected for individual subjects through the measurement of increasing volumes of PB, we have built a mathematical algorithm that would allow prediction of the frequency of MBL cases carrying a small CLL-like clone, if larger volumes of blood from individual subjects would have been screened. Based on this model, our results suggest that the vast majority of healthy adults would have a detectable clone of CLL-like B-cells if larger blood volumes had been screened. In fact, the frequency of expected MBL cases among healthy subjects would raise up to 100% for subjects older than 70 years. Confirmation of the presence of CLL-like B-cell populations in 8/9 adults who were initially negative, through the analysis of large volumes of PB (for example, 50 ml), confirms this hypothesis; the exact frequency remains to be determined in this as well as in the other younger age-groups. Interestingly, among these cases, a high frequency of subjects in whom both sIgk þ and sIgl þ CLL-like B-cells were present, was found. In-line with these findings, recent results in relatives of CLL patients also found multiclonal CLL-like B-cells in 4/6 MBL cases with low MBL counts. 8 Altogether, these results support the hypothesis that the presence of CLL-like B-cells may be a physiological phenomenon in adults with normal lymphocyte counts. If this holds true, it could be expected that (i) CLL-like B-cell numbers would be lower among multiclonal vs monoclonal cases and (ii) the frequency of CLL-associated genetic abnormalities would significantly decrease at lower MBL counts. In-line with this hypothesis, in 14/35 fluorescence-activated cell sorter-purified CLL-like B-cell populations investigated for cytogenetic abnormalities (purity 497%) by interphase fluorescence in situ hybridization, cytogenetic changes were detectedFtrisomy 12 in 2 (6%) cases and del(13q) in 12 (36%) subjectsF and these MBL cases showed an absolute number of CLL-like B-cells significantly higher than that found for the other 21 MBL cases in whom no cytogenetic abnormalities were detected by interphase fluorescence in situ hybridization: median of 32 (minimum-maximum values of 8 and 56) and 11.5 (minimum-maximum values of 0.55 and 1172) CLL-like B-cells per ml in those cases carrying trisomy 12 and del(13q), respectively, vs a median of 0.56 (minimum-maximum values of 0.1 and 8) CLL-like B-cells per ml for the other cases with no cytogenetic abnormalities by interphase fluorescence in situ hybridization (P ¼ 0.001); notably, none of the cases carrying trisomy 12 and only 2/12 cases with del(13q) showed less than 1 PB CLL-like B-cell per ml, whereas 11/21 cases without detectable genetic abnormalities were 'low-count' MBL (o1 circulating CLL-like B-cell per ml). Whether the higher tendency to be monoclonal vs polyclonal, and to have detectable genetic abnormalities, as the number of CLL-like MBL cells increases would be relevant in the outcome of MBL, requires further investigation. Further studies in which the functional role of these CLL-like cells is investigated are necessary to confirm this hypothesis and determine the potential nature of the chronic antigen stimuli leading to the emergence of CLL-like B-cells in healthy adults and transformation to CLL; however, these are not easy to perform, because of the limited number of cells that can be obtained in cases with very low MBL counts.
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